Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study
Authors' conclusion
In this real-world, adult population with T2D in Japan, FRC therapy was associated with improved adherence and persistence versus free combination therapy.
Study context
- Population
- Adults (≥18 years) with confirmed T2D and ≥1 prescription for a GLP-1 RA (with predefined basal insulin persistence window) or an fixed-ratio combination (FRC), October 2019 to September 2023, DeSC-IQVIA Integrated claims data, Japan
- Participants
- 2,386 vs 2,063
- Exposure
- FRC therapy vs free combination of basal insulin and injectable GLP-1 RA
- FRCn = 2,386
- Free combinationn = 2,063reference
- Outcome
- Adherence to and persistence with free combination vs FRC therapy
- Follow-up
- 365 days
Methodological detailsobservational, claims database
- Observational
- Claims database
Main finding
As reported in the abstract
end of follow-up
Each group vs free combinationEstimate (95% CI)P value
FRC
aOR for optimal adherence 1.96(1.73–2.23)
P < 0.001FRC
aHR for discontinuation 0.66(0.61–0.71)
P < 0.001Observational data: associations, not effects.
Further findings
Age at index
P = 0.002
Adherence and persistence in elderly individuals
- Adherence and persistence findings were similar in elderly individuals
Original publication
Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study. Diabetes Obes Metab. Published 5 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →